Market News

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Reports Increase in Sellers; Strong Momentum for Short Players

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Logo

Investors sentiment decreased to 1.34 in Q2 2018. Its down 0.97, from 2.31 in 2018Q1. It turned negative, as 12 investors sold Paratek Pharmaceuticals, Inc. shares while 26 reduced holdings. 14 funds opened positions while 37 raised stakes. 20.80 million shares or 1.20% more from 20.55 million shares in 2018Q1 were reported.
Fortress Investment Grp Ltd Llc has 433,804 shares for 0.18% of their portfolio. Gp invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Cutter Brokerage Incorporated invested in 10,150 shares or 0.04% of the stock. California Employees Retirement Systems has 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 120,400 shares. Manufacturers Life Ins The holds 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) or 25,550 shares. Cadence Cap Mgmt reported 78,372 shares or 0.05% of all its holdings. Wells Fargo And Com Mn holds 0% or 38,587 shares. Bnp Paribas Arbitrage reported 1,002 shares or 0% of all its holdings. Rhumbline Advisers invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Trexquant Investment L P accumulated 24,336 shares. Royal State Bank Of Canada holds 0% or 666 shares. Geode Cap Mngmt Ltd Co has 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Ameritas Invest Ptnrs reported 2,069 shares or 0% of all its holdings. Morgan Stanley has invested 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Weiss Multi has 0.01% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) registered an increase of 12.97% in short interest. PRTK’s total short interest was 6.94 million shares in October as published by FINRA. Its up 12.97% from 6.14M shares, reported previously. With 354,600 shares average volume, it will take short sellers 20 days to cover their PRTK’s short positions. The short interest to Paratek Pharmaceuticals Inc’s float is 28.35%.

The stock decreased 0.43% or $0.04 during the last trading session, reaching $9.34. About 506,555 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 62.88% since October 21, 2017 and is downtrending. It has underperformed by 78.50% the S&P500.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. The company has market cap of $296.35 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. It currently has negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.

More notable recent Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) news were published by: which released: “After-Hours Stock Movers 10/04: (SGH) (PRTK) Higher; (HSGX) (KMPH) (CUTR) Lower (more…)” on October 04, 2018, also with their article: “EMA accepts Paratek’s omadacycline marketing application” published on October 04, 2018, published: “FDA Approves Paratek’s Bacterial Pneumonia, Skin Infection Treatment” on October 03, 2018. More interesting news about Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) were released by: and their article: “Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018” published on September 25, 2018 as well as‘s news article titled: “Paratek announces FDA approval of NUZYRA” with publication date: October 03, 2018.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *